chrisvoncsefalvay/vaers-outcomes huggingface dataset:
Peri-orbital swelling on 6/23 which resolved followed by pruritic rash on legs and chest.  Facial swelling & polymorphous rash on 6/28.
Information has been received from a health professional concerning a female patient who was vaccinated with a dose of pneumococcal 23v polysaccharide vaccine (lot 649913/0577P). Subsequently, the patient experienced pain and tenderness, accompanied by fever, chills, and swelling from her shoulder to her elbow. Within four days, the symptoms abated and the patient recovered. Unspecified medical attention was sought. No product quality complaint was involved. Additional information is not expected. It was also reported a patient was vaccinated with a dose of pneumococcal 23v polysaccharide vaccine  (WAES0501USA02933) and experienced adverse events.
She became symptomatic for covid 1/8/21 and tested positive 1/11/21.; Slight occasional cough; This spontaneous case was reported by a physician and describes the occurrence of COVID-19 (She became symptomatic for covid 1/8/21 and tested positive 1/11/21.) and COUGH (Slight occasional cough) in a 60-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     The patient's past medical history included DVT of calf (~35 years ago). Concurrent medical conditions included Hypertension. Concomitant products included METOPROLOL and VERAPAMIL HYDROCHLORIDE (CALAN [VERAPAMIL HYDROCHLORIDE]) for an unknown indication.    On 28-Dec-2020, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 06-Jan-2021, the patient experienced COUGH (Slight occasional cough). On 11-Jan-2021, the patient experienced COVID-19 (She became symptomatic for covid 1/8/21 and tested positive 1/11/21.). The patient was treated with DEXTROMETHORPHAN HYDROBROMIDE (DELSYM) for COVID-19 and Cough, at a dose of UNK dosage form. At the time of the report, COVID-19 (She became symptomatic for covid 1/8/21 and tested positive 1/11/21.) and COUGH (Slight occasional cough) outcome was unknown. Not Provided    DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On 11-Jan-2021, SARS-CoV-2 test: positive Positive.     The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   The patient is improving well so far, and is afebrile.
Patient came in for sports PE. After examination done, PPD and HPV #1 were ordered and placed. Pt observed for 15 minutes. However, while checking out with Mom, patient had syncope < 5 secs (witnessed by Mom and front office). Patient stabilized, O2 sat (100%) and EKG (WNL) ordered.
Low grade fever, HA, fatigue, pain and swelling at the injection site.  Tylenol and Motrin with improvement.
My COVID-19 symptoms started on 03/29/2023 in the afternoon. I had fatigue, headaches, and nasal congestions. On the 03/30/2023 before going to work I tested myself and it was positive. I did a telehealth with my doctor who then prescribed me PAXLOVID for 5 days. On 04/05/2023 I tested negative. As of today I still have fatigue, runny nose and sinus/nasal symptoms but I tested negative.
were supposed to be given DTaP and IPV separately instead they were given QUADRACEL with no adverse event; Initial information was received on 25-Jan-2021 regarding an unsolicited valid non-serious case from a other health professional.  This case is linked to case 2021SA031955 (same reporter).  This case involves a 4-month-old male patient who was administered DIPHTHERIA-15/TETANUS/5 HYBRID AC PERTUSSIS/IPV (MRC5) VACCINE [QUADRACEL] (lot C5755AB, expiry date 10-Jul-2022) via intramuscular route in the right thigh instead they were supposed to administer DIPHTHERIA-15/TETANUS/5 AC PERTUSSIS VACCINE [DAPTACEL] and POLIOMYELITIS VACCINE (INACTIVATED) separately (lot number and expiry date not reported) for prophylactic vaccination on 15-Jan-2021 (wrong product administered).  Medical history, medical treatment(s), vaccination(s) and family history were not provided.  Concomitant medications included HIB VACCINE CONJ (TET TOX) (HIBERIX); ROTAVIRUS VACCINE (ROTAVIRUS VACCINE); and PNEUMOCOCCAL VACCINE 13V (PNEUMOCOCCAL 13 VALENT VACCINE).  This was a case of actual medication error due to wrong vaccine administered (latency same day).  At the time of report, no adverse event was reported.  This suspected adverse reaction report is submitted and classified as a medication error solely and exclusively to ensure the marketing authorization holders compliance with the requirements. The classification as a medical error is in no way intended, nor should it be interpreted or construed as an allegation or claim made by the marketing authorization holder that any third party has contributed to or is to be held liable for the occurrence of this medication error.
Approx 40-45 days following vaccine receipt, developed left facial pain across jaw and zygomatic arch, worse at night. No numbness or tingling. No visual or other sensory sx's. No rashes. 11/12/09, Seen by PCM --> A/P: Trigeminal Neuralgia vs muscle strain w/(+) masseter/buccinator trigger points --> NEURONTIN; ROBAXIN, PM&R, Facial MRI (Pending); seen by Dentist - pain not felt to be r/t dental issues). Symptoms: Pain.
Pruritic rash on torso and face, patient treated with antihistamine and improved, felt to be secondary to antibiotic.
Local edema, erythema, and induration with bruising.  Had mild systemic symptoms that resolved in 2-3 days.  Onset of reaction within 6 hours.
Swelling in the groin area above the hip; skin is swollen and there is lump; skin is swollen and there is lump; This is a spontaneous report from a contactable consumer. A 74-years-old male patient received BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE, lot number: EL1284), via an unspecified route of administration on 18Jan2021 at first single dose for covid-19 immunisation. Medical history included: the patient had pre-existing conditions, he was hospitalized in Dec2020 and he was undergoing a lot of testing and there was possibility that he had a form of cancer and they discovered something on the next to his lungs. The reporter stated they did not have all of the diagnosis of it yet and he was waiting to be seen for specialist. The patient's concomitant medications were not reported. On 20Jan2021, the patient had a swelling. Swelling in the groin area above the hip. Skin is swollen and there is a lump. The reporter was trying to find out with the list of side effects if the lymph glands can swell and what areas of the body would you may be see swelling in the lymph nodes. The reporter wonder if there be lymph gland located for the men or the lymph gland located on the either side of the reproductive organ, in that area. What had happened to the patient, they were not sure if that was a side effect. One of the side effects the reporter knew it was listed on the website was lymph glands swell up. So the reporter just trying to find out if there were lymph glands in that same area where the patient was experience swelling right now. He did not have this issue before he got the vaccine, so it just sort of seemed this is. The reporter talked to the physician's office briefly when this happened just to see did they need to bring the patient in immediately for an appointment to check if it's (incomplete sentence). So far the patient just received topical ice packs over the area for the events. Outcome of the events was unknown.
This spontaneous report as received from a pharmacist refers to a patient of unknown age and gender. No pertinent medical history, concurrent conditions or drug reactions/ allergies were reported. On 04-JAN-2017, the patient was vaccinated with an improperly stored dose of ZOSTAVAX (which had a lot # reported as M036616 with an expiration date of 19-NOV-2017; however, the dose, dosage number, route of administration, and anatomical location were unknown) for prophylaxis. No concomitant therapies were reported. Reportedly, the vaccine had experienced a temperature of 36 F to 46 F for a time frame of 2 hours. The call was made due to a data logger. Lot # M036616 was determined to not be valid lot number for ZOSTAVAX. Additional information has been requested.
Menstruation is controlled to the day by birth control. The next cycle after the second vaccination, I started bleeding two weeks into the package of pills, which is full hormones. Irregular cycles, unusually heavy bleeding, and very long periods continued for the next 6 months. I have only had one normal cycle since, and it has been the most recent. It's unknown if it has resolved.
Patient is complaining of extreme soreness at the sight of injection. That the pain has not gone away after over a month. She went to her primary care doctor, they told her it was from getting the shot way too high up on the arm near the shoulder.
NOT FEELING GOOD; This spontaneous case was reported by a consumer and describes the occurrence of MALAISE (NOT FEELING GOOD) in a 64-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.    Co-suspect product included non-company product ADALIMUMAB (HUMIRA) for Hidradenitis suppurativa.  No Medical History information was reported.   On 01-Aug-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On an unknown date, the patient started ADALIMUMAB (HUMIRA) (Subcutaneous) at an unspecified dose. In August 2021, the patient experienced MALAISE (NOT FEELING GOOD). In August 2021, MALAISE (NOT FEELING GOOD) had resolved.     The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   This case was identified as part of a retrospective clean-up activity where certain emails received in the Moderna mailbox were missed to be booked-in.  No concomitant medication information was provided.  It was unknown if patient was enrolled in a COVID-19 vaccine trial.  No treatment medication was provided.
I tested positive for Covid on 4/24/21. My symptoms are sinus pressure and congestion, headache and fatigue
Patient developed lymphadenopathy of inferior end of left superficial cervical chain approx. 2cm diameter when examined on 8/14/2020.  No treatment.  Recommended observation and RTC if symptoms worsened
was very tired and is still tired; arm was also sore; She felt lousy like she did not want to do anything; This spontaneous case was reported by a consumer and describes the occurrence of FATIGUE (was very tired and is still tired), PAIN IN EXTREMITY (arm was also sore) and MALAISE (She felt lousy like she did not want to do anything) in a 73-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 029K20A) for COVID-19 vaccination.     No Medical History information was reported.    On 04-Feb-2021, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) at an unspecified dose. On 04-Feb-2021, the patient experienced FATIGUE (was very tired and is still tired), PAIN IN EXTREMITY (arm was also sore) and MALAISE (She felt lousy like she did not want to do anything). At the time of the report, FATIGUE (was very tired and is still tired), PAIN IN EXTREMITY (arm was also sore) and MALAISE (She felt lousy like she did not want to do anything) outcome was unknown. Not Provided      The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       Treatment information not provided. Concomitant medications were not provided.
Arm has a warm red splotch below the injection site; Arm has a warm red splotch below the injection site; This is a spontaneous report from a contactable consumer, the patient. A 61-year-old male patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ER8734) via an unspecified route of administration in the right arm on 05Apr2021 at 09:00 (at the age of 61-year-old) as a single dose for COVID-19 immunisation. Medical history included blood pressure high. The patient did not have any allergies to food, medications, or other products. The patient received unspecified medication within two weeks of vaccination. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EN6206) via an unspecified route of administration in the right arm on 15Mar2021 at 09:30 (at the age of 61-year-old) as a single dose for COVID-19 immunisation. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 07Apr2021, the patient experienced her arm had a warm red splotch below the injection site. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The patient did not receive any treatment for the events. The clinical outcome of the events arm has a warm red splotch below the injection site was not resolved.  No follow-up attempts are needed. No further information is expected.
930 AM - Injection. 11 AM - Cough dry. 1 PM - Increased congestion. 3 PM - Wheezing - headache - overall body ache.
Moderna Booster (0.25ml) vaccine was drawn up after max 20 drawn doses allowed. Proper aseptic techniques were used during dose extraction and vaccine was inspected prior to administration. Patient was given correct dose (0.25ml) and was monitored for 15 minutes after vaccination. No adverse event/ reaction occurred after administration.
Mixed product; Headache; Chills; This spontaneous case was reported by an other health care professional and describes the occurrence of INTERCHANGE OF VACCINE PRODUCTS (Mixed product), HEADACHE (Headache) and CHILLS (Chills) in a 57-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     Previously administered products included for COVID-19 vaccination: COVID-19 VACCINE ASTRAZENECA on 23-Mar-2021. Past adverse reactions to the above products included No adverse event with COVID-19 VACCINE ASTRAZENECA.    On 26-Jun-2021, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 26-Jun-2021, the patient experienced INTERCHANGE OF VACCINE PRODUCTS (Mixed product), HEADACHE (Headache) and CHILLS (Chills). On 26-Jun-2021, INTERCHANGE OF VACCINE PRODUCTS (Mixed product) had resolved. On 29-Jun-2021, HEADACHE (Headache) and CHILLS (Chills) had resolved.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   Concomitant medication was not provided.  Treatment information was not provided.  Patient received her first dose of AstraZeneca on 23-March-2021 and second dose of Moderna on 26-June 2021. Patient experienced headache and chills for about 2-3 days following the Moderna shot.
This spontaneous report was received from a nurse and refers to an unspecified number of patients of unknown age and gender. No information regarding the patients' medical history, concurrent conditions and concomitant therapies was provided. On 23-NOV-2015, the patients were vaccinated with improperly stored doses of RECOMBIVAX HIB (lot # L016427 and expiration date 13-APR-2017, lot # L018501 and expiration date 22-JUN-2017, lot # L025738 and expiration date 14-AUG-2017, exact doses and route of administration were not reported). It was unknown which of the lots of the vaccine were administered on that date, so all lots fro the product were listed. No adverse events were reported. No PQC (product quality complaint) was involved. This is one of several reports received from the same source. Additional information has been requested.
Patient received Typhoid vaccine when she was not in fact due for it. Patient was due for Tdap instead. Clinic provider, Dr., notified of incident and patient/staff reviewed. Patient was then administered correct dose of Tdap in right arm.
Local reaction at injection site, 5x8cm red area, tender, started 10/25/2005.  Fever 104.7, vomiting, diarrhea, joint pain, decreased intake, decreased output, rash scattered, red flat area on arms, legs, trunk, and neck.
injection-site - pain, redness. Also fatigue, headache, shivering, fever, and gastrointestinal issues.
Patient reports after receiving dose 3 (Booster) COVID vaccine 10/15/2021 she developed left sore arm, migraine headache, fever 102.5, myalgia, fatigue, right eye Hordeolum, and left arm is erythematous, warm to touch, and swollen over the site of injection after the vaccine.  Reports the onset of symptoms started approximately 12 hours after injection.  Patient has been applying ice and heat to left arm, which has not helped.  Patient reports she has been apply wet warm compresses to right eye, which has decreased the size of the Hordeolum but it is still present.    Physical exam: left arm over deltoid warm to touch, firm nodule 1 cm x 0.5 cm palpated over deltoid over injection site.  no erythema or lymphatic streaking.  right eye external hordeolum to medial canthus, no erythema, streaking, or periorbital swelling.  Tenderness upon palpation.
Narrative: Pt received Moderna Covid vaccine #1 on 4/9/21 and on 4/14/21, his date of death was recorded. No CPRS notes or scanned records to indicate events from date of vaccine to date of death; however it appears that he was under hospice care. There was 5 days from date of vaccine to date of death. No autopsy report available.
8 days after the vaccine there was a welt under my skin 3 inches long that was sore. The next day the welt turned red and began to itch. Two days later the welt, pain, and itch went away. Today is day 13 and I still have a large red mark on my arm where the injection site is.
Vaccine given left arm 10/6/08. 10/7/08 in afternoon started with nausea and hives over most of body. vomited x 2. Nausea resolved by 10/8/08 and hives persist upon my exam this PM (10/9/0) Hives on exam predominately upper body left arm worse than right. After detailed history could not find any other known triggers. No fever or other systemic symptoms.
COVID-19; COVID-19; This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP). The reporter is the patient.  A 67-year-old female patient (not pregnant) received BNT162b2 (BNT162B2), on 10Feb2021 as dose 1, single (Batch/Lot number: unknown), on 01Sep2021 as dose 2, single (Batch/Lot number: unknown) and on 05Jan2022 as dose 3 (booster), single (Batch/Lot number: unknown) at the age of 67 years for covid-19 immunisation. The patient's relevant medical history included: "Heart disease - stent." (unspecified if ongoing); "Hypoactive thyroid" (unspecified if ongoing). The patient's concomitant medications were not reported. The following information was reported: DRUG INEFFECTIVE (medically significant), COVID-19 (medically significant), outcome "not recovered" and all described as "COVID-19". Therapeutic measures were not taken as a result of drug ineffective, covid-19. Clinical information of the events: Adverse event: Rebound COVID symptom 5 days after last dose of PAXLOVID. Runny nose, fever, chills, sneezing and cough. patient recovered: Not Recovered. No treatment received. No Known allergies.  The information on the batch/lot number for BNT162b2 has been requested and will be submitted if and when received.
Moderna COVID-19 vaccine  Right arm: site itches, site is oval shape,  raised  .5 inches,  rash  located on lefft side.  Itching is controlled with Triamcinolone topical cream.  I am taking 50mg (2 tabs) of Benadryl every four (4) hours.   I am using Albuterol Ipratropium .5mg/3mg per 3ml, 1 vial soution into nebulizer every six (6) hours or has neede to breathe easier.  I have a tracheostomy due to the GPA, disease, below my vocal cords.
This spontaneous report was received from a health care worker refers to an unspecified patient. Patient medical history and current condition was not reported. On 08-MAY-2015 the patient was vaccinated with improperly stored dose of VAQTA (unspecified strength, dose and frequency). No adverse effect reported. The outcome of the event was unknown. Additional information has been requested.
Severe hives on arms, legs, and torso. Elevated temperature of between 99-100 F. Began at 11:00pm on Apr 5, 2021, about 12 hours after vaccination. Hives severity continues to increase on Apr 6, 2021 as of about 24 hours after vaccination. Has not yet recovered. Monitoring.
no adverse event to report as of today -- patient was counseled that 2nd dose of vaccine may be less effective since it was given outside the recommended 42 day window -- first dose given 5/17/21
No adverse effects reported; unspecified 29 year old patient inadvertently received a dose of PROQUAD; Information has been received from a pharmacy intern referring to a 29 year old patient of unknown gender. Concomitant therapy included sterile diluent. The patient's pertinent medical history, drug reactions/allergies and concurrent condition were not provided.   On an unspecified date in May 2019, the patient inadvertently received measles, mumps, rubella and varicella (oka-merck) virus vaccine live (PROQUAD) (1 dosage form; strength, frequency, route, batch/lot number and expiration date were unknown) for prophylaxis at an unspecified location (Adult use of a child product). No adverse effects were reported.
A few hours post vax, the pt developed bumps at and around the injection site. The rash persisted for almost one week and disappeared. Pt treated with cold compress and Benadryl.
Patient noticed a rash on her left thigh few hours after the second dose; This spontaneous case was reported by a consumer and describes the occurrence of RASH (Patient noticed a rash on her left thigh few hours after the second dose) in a 49-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 013M20A) for COVID-19 vaccination.     No Medical History information was reported.   On 25-Feb-2021, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to dosage form. On an unknown date, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) at an unspecified dose. On 25-Feb-2021, the patient experienced RASH (Patient noticed a rash on her left thigh few hours after the second dose). At the time of the report, RASH (Patient noticed a rash on her left thigh few hours after the second dose) outcome was unknown.             No relevant concomitant medications were reported. No treatment information was provided.   Action taken with mRNA-1273 in response to the event was not applicable.